Combination of oxidative phosphorylation and platelet-derived growth factor inhibitors for the treatment of ovarian cancers.

Authors

Kathleen M Burkhard, Taylor Repetto, Geeta Mehta

Published in

npj women's health. Volume 4. Issue 1. Pages 22. Epub May 07, 2026.

Abstract

The combination therapy of FDA approved oxidative phosphorylation inhibitors (metformin and atovaquone) and platelet derived growth factor inhibitors (sunitinib and sorafenib) could target ovarian cancer stem-like cells (CSCs) and carcinoma associated mesenchymal stem cell enrichment of CSCs while reducing off-target effects. Results of a 48-hour drug exposure ovarian cancer-MSC tumoroid model showed additive effects with atovaquone combined with sunitinib or sorafenib being most effective.

PMID:
42453943
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.